glp 1 agonist new GLP-1 Guidelines for Type 2 Diabetes in 2025 GLP-1 Agonists Market Report 2025-2033,

Supplementary Information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made

Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

In April 2025 the company announced it was struggling with more than US $1.4 billion debt and were filing for bankruptcy (Ferguson)

Source Data Extended Data Fig./Table 1 (download XLSX Statistical source data

Combining GIP and GLP-1R agonism was first discovered and reported a decade ago 40 and has now fully evolved as the GIP/GLP-1R co-agonist tirzepatide that can achieve more than 20% weight loss in obesity as well as offering superior benefits in diabetes

In preclinical models of polymicrobial sepsis, such as the cecal slurry and cecal ligation puncture (CLP) models, long-acting GLP-1 receptor agonists (GLP-1RAs) like semaglutide have demonstrated protective effects